Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2020—Verichem Laboratories announced the availability of its HDL Cholesterol Verifier kit intended for the calibration verification of HDL and LDL cholesterol assays. The kit contains high-density and low-density lipoprotein cholesterol from human serum in a ready-to-use, liquid stable format that is free of surfactants, glycols, and azide.
February 2020—Roche announced FDA approval of Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial treatment of adults with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations. The European Commission approved the combination therapy in September.
February 2020—Foundation Medicine has received FDA approval for its FoundationOne CDx to be used as a companion diagnostic for Piqray (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor–positive, human epidermal growth factor receptor 2–negative, PIK3CA-mutated advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.
February 2020—Quest Diagnostics has acquired certain assets of the clinical laboratory services business of Boston Clinical Laboratories, based in Waltham, Mass.
February 2020—The FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting. Enhertu is a human epidermal growth factor receptor 2–directed antibody and topoisomerase inhibitor conjugate.
February 2020—Siemens Healthineers announced the availability of its Enhanced Liver Fibrosis testing service in the United States, excluding New York State, and Puerto Rico. The testing service is provided by the Siemens Healthcare Laboratory.
January 2020—Olympus introduced its Slideview VS200 slide scanner, designed to capture high-resolution images for quantitative analysis for brain, cancer, and stem cell research, as well as drug discovery. The scanner uses Olympus X Line objectives, which are designed to deliver flatter images with a wide field of view and no intensity fall off at the periphery, improve numerical aperture, and offer a wider range of chromatic correction.
January 2020—Genentech announced positive data from the phase three IMpower110 study evaluating Tecentriq (atezolizumab) as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced nonsquamous and squamous non-small cell lung cancer without ALK or EGFR mutations.
January 2020—ALPCO announced that the FDA granted its Calprotectin Chemiluminescence ELISA 510(k) clearance. It is intended for in vitro diagnostic use as an aid in the diagnosis of inflammatory bowel disease, specifically Crohn’s disease and ulcerative colitis, and as an aid in the differentiation of IBD from irritable bowel syndrome, in conjunction with other clinical and laboratory findings.
January 2020—Personal Genome Diagnostics received the CE mark for the PGDx Elio Tissue Complete assay. The panel is a 507-gene test for somatic alterations that detects single nucleotide variants, small indels, amplifications, rearrangements, microsatellite instability, and tumor mutation burden.
